POLARIS

Addendum zu interventionellen Studie

01.12.2016 bis 31.08.2018

Addendum No. 2 zur Studie: Multicenter, randomized, open-label, efficacy assessor-blinded, active comparator-controlled phase 3b study to compare the efficacy of guselkumab to fumaric acid esters (Fumaderm initial/Fumaderm) for adult patients with moderate to severe plaque psoriasis who are candidates for and naive to systemic treatment.